JP2018537975A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537975A5
JP2018537975A5 JP2018527739A JP2018527739A JP2018537975A5 JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5 JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018527739 A JP2018527739 A JP 2018527739A JP 2018537975 A5 JP2018537975 A5 JP 2018537975A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018527739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018537975A (ja
JP6979950B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/057017 external-priority patent/WO2017093844A1/en
Publication of JP2018537975A publication Critical patent/JP2018537975A/ja
Publication of JP2018537975A5 publication Critical patent/JP2018537975A5/ja
Application granted granted Critical
Publication of JP6979950B2 publication Critical patent/JP6979950B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018527739A 2015-11-30 2016-11-22 部位特異的ｈｅｒ２抗体薬物コンジュゲート Expired - Fee Related JP6979950B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562260854P 2015-11-30 2015-11-30
US62/260,854 2015-11-30
US201662289744P 2016-02-01 2016-02-01
US201662289727P 2016-02-01 2016-02-01
US62/289,744 2016-02-01
US62/289,727 2016-02-01
US201662409105P 2016-10-17 2016-10-17
US62/409,105 2016-10-17
PCT/IB2016/057017 WO2017093844A1 (en) 2015-11-30 2016-11-22 Site specific her2 antibody drug conjugates

Publications (3)

Publication Number Publication Date
JP2018537975A JP2018537975A (ja) 2018-12-27
JP2018537975A5 true JP2018537975A5 (OSRAM) 2020-01-16
JP6979950B2 JP6979950B2 (ja) 2021-12-15

Family

ID=57485830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018527739A Expired - Fee Related JP6979950B2 (ja) 2015-11-30 2016-11-22 部位特異的ｈｅｒ２抗体薬物コンジュゲート

Country Status (17)

Country Link
US (2) US10689458B2 (OSRAM)
EP (1) EP3383918A1 (OSRAM)
JP (1) JP6979950B2 (OSRAM)
KR (2) KR102208317B1 (OSRAM)
CN (1) CN108473591B (OSRAM)
AU (1) AU2016363373A1 (OSRAM)
BR (1) BR112018010102A2 (OSRAM)
CA (1) CA2949032A1 (OSRAM)
CO (1) CO2018005433A2 (OSRAM)
IL (1) IL259651B2 (OSRAM)
MX (1) MX2018006582A (OSRAM)
PH (1) PH12018501043A1 (OSRAM)
RU (1) RU2745565C2 (OSRAM)
SG (2) SG11201803676PA (OSRAM)
TW (3) TWI778491B (OSRAM)
WO (1) WO2017093844A1 (OSRAM)
ZA (1) ZA201803205B (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
IL310865A (en) * 2016-10-17 2024-04-01 Pfizer Antibodies against EDB and antibody-drug conjugates
CN111163809B (zh) 2017-09-19 2024-07-02 保罗·谢勒学院 转谷氨酰胺酶缀合方法和接头
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
CN114901308A (zh) * 2019-10-29 2022-08-12 石药集团巨石生物制药有限公司 使用抗her2抗体药物缀合物治疗癌症的组合物和方法
CA3165135A1 (en) * 2019-12-20 2021-06-24 Pfizer Inc. Treatment with site specific her2 antibody-drug conjugates
WO2021143741A1 (zh) * 2020-01-15 2021-07-22 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
BR112023002154A2 (pt) 2020-08-04 2023-03-14 Pfizer Tratamento com conjugados anticorpo-fármaco anti-her2 de local específico
CN112202628B (zh) * 2020-09-08 2022-09-02 杭州涂鸦信息技术有限公司 一种WiFi模块串口协议自动化测试系统及方法
CN112285361B (zh) * 2020-09-27 2023-12-05 中国人民解放军空军军医大学 排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
WO2022084560A1 (en) 2020-10-25 2022-04-28 Araris Biotech Ag Means and methods for producing antibody-linker conjugates
AU2022222937A1 (en) * 2021-02-18 2023-08-17 Remegen Co., Ltd. Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer
CN118434759A (zh) * 2021-10-10 2024-08-02 安立玺荣生医(香港)有限公司 用抗-pd-l1/il-10融合蛋白治疗疾病的方法
JP2024539989A (ja) * 2021-10-25 2024-10-31 アラリス バイオテック アーゲー 抗体－リンカーコンジュゲートを生成する方法
MX2024009292A (es) * 2022-01-26 2024-08-06 Biocytogen Pharmaceuticals Beijing Co Ltd Anticuerpos anti-her2/trop2 y usos de los mismos.
WO2024162772A1 (ko) * 2023-02-01 2024-08-08 주식회사 에이티지씨 생체 내 지속성이 증가된 생리활성물질의 결합체
CN120738196B (zh) * 2025-09-03 2025-12-16 浙江博锐生物制药有限公司 编码抗her2抗体的核酸分子及其应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9116610D0 (en) 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
WO2000053211A2 (en) 1999-03-09 2000-09-14 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
WO2001062299A2 (en) 2000-02-28 2001-08-30 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CA2567520A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Maytansinoid-antibody conjugates
RS53594B1 (sr) 2004-07-22 2015-02-27 Genentech, Inc. Preparat her2 antitela
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2598833A1 (en) 2005-03-03 2006-09-08 Curt W. Bradshaw Anti-angiogenic compounds
CN101312748A (zh) 2005-09-26 2008-11-26 梅达莱克斯公司 抗体-药物轭合物和使用方法
JPWO2008032833A1 (ja) 2006-09-14 2010-01-28 株式会社医学生物学研究所 Ａｄｃｃ活性を増強させた抗体及びその製造方法
US20090098115A1 (en) * 2006-10-20 2009-04-16 Lisa Michele Crocker Cell lines and animal models of HER2 expressing tumors
JP5606916B2 (ja) 2007-10-19 2014-10-15 ジェネンテック， インコーポレイテッド システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体
ES2613963T3 (es) 2008-01-18 2017-05-29 Medimmune, Llc Anticuerpos manipulados con cisteína para conjugación específica de sitio
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc Cycteine engineering anti-cd79b antibodies and antibody-drug conjugates
EP2711018A1 (en) 2009-06-22 2014-03-26 MedImmune, LLC Engineered Fc regions for site-specific conjugation
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
ME02637B (me) 2010-08-20 2017-06-20 Novartis Ag Antitela za receptor 3 faktora rasta epiderma (her3)
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
CA2818635C (en) 2010-12-06 2021-06-15 National Reseach Council Of Canada Antibodies selective for cells presenting erbb2 at high density
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
WO2013072813A2 (en) * 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
EP2844289B1 (en) 2012-04-30 2019-07-17 MedImmune, LLC Molecules with reduced effector function and extended half-lives, compositions, and uses thereof
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
US9540442B2 (en) 2012-08-02 2017-01-10 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
WO2014022846A1 (en) 2012-08-03 2014-02-06 Board Of Regents Of The University Of Nebraska Cancer biomarkers and methods of use thereof
KR20150083856A (ko) 2012-10-12 2015-07-20 에이디씨 테라퓨틱스 에스에이알엘 피롤로벤조디아제핀-항-her2 항체 컨주게이트
CN110256469B (zh) 2012-10-12 2022-05-17 麦迪穆有限责任公司 吡咯并苯并二氮杂卓及其结合物
AU2013343111A1 (en) 2012-11-07 2015-05-14 Pfizer Inc. Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates
SI2953976T1 (sl) * 2013-02-08 2021-08-31 Novartis Ag Specifična mesta z modificiranje protiteles za izdelavo imunokonjugatov
NZ710745A (en) 2013-03-13 2019-03-29 Genentech Inc Pyrrolobenzodiazepines and conjugates thereof
KR101899306B1 (ko) 2013-07-03 2018-10-04 서울대학교산학협력단 시스테인으로 변형된 닭의 항체 및 이를 이용한 부위-특이적 접합
BR112016002829A2 (pt) 2013-08-12 2017-09-19 Genentech Inc Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
US9239324B2 (en) 2013-12-06 2016-01-19 Gang Chen Antibody-binding protein-drug conjugate and methods of use
PL3086814T3 (pl) 2013-12-23 2020-12-28 Bayer Pharma Aktiengesellschaft Koniugaty środka wiążącego (ADC) z inhibitorami KSP
PE20161031A1 (es) 2014-01-27 2016-10-26 Pfizer Agentes citotoxicos bifuncionales
RS66392B1 (sr) * 2014-02-28 2025-02-28 Merus Nv Antitelo koje vezuje erbb-2 i erbb-3
HK1232127A1 (zh) 2014-04-11 2018-01-05 Medimmune, Llc 双特异性her2抗体
CN106456608B (zh) * 2014-06-06 2020-08-28 雷德伍德生物科技股份有限公司 抗her2抗体-美登木素缀合物及其使用方法
WO2016151432A1 (en) 2015-03-20 2016-09-29 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore
CA2949033C (en) 2015-11-30 2025-05-06 Pfizer Inc. ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION

Similar Documents

Publication Publication Date Title
JP2018537975A5 (OSRAM)
RU2018119683A (ru) Сайт-специфические конъюгаты антитела к her2 и лекарственного средства
TWI847992B (zh) 抗體-藥物結合物之有效的製造方法
CN120248020B (zh) 生物活性物偶联物及其制备方法和用途
TWI722422B (zh) 抗體-藥物結合物
JP6847388B2 (ja) 生物活性分子、そのコンジュゲート、及び治療用途
AU2019320336B2 (en) Combination of antibody-drug conjugate and tubulin inhibitor
AU2015205588B2 (en) Duocarmycin ADCs for use in treatment of endometrial cancer
JP2017186337A5 (OSRAM)
JP2019532056A5 (OSRAM)
JP2015534577A5 (OSRAM)
JP2016502504A5 (OSRAM)
FI3283521T3 (fi) Lääkekonjugaatteja käsittäen vasta-aineita claudiinia 18.2 vastaan
JP2017514905A5 (OSRAM)
ME02919B (me) Konjugati humanog antitijela sa lijekom protiv tkivnog faktora
JP2016505513A5 (OSRAM)
JP2012522512A5 (OSRAM)
CN118973617A (zh) 缀合物、组合物及使用方法
CN106999606A (zh) 抗体药物偶联物
JP2016540826A5 (OSRAM)
JP2020507569A5 (OSRAM)
TW202525806A (zh) 基於分子膠降解劑之抗體-藥物結合物及其用途
TWI906070B (zh) 抗體-藥物結合物之用途
JP2025540063A (ja) 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用
BR122024023393A2 (pt) Uso de um conjugado de anticorpo-fármaco, composição farmacêutica, e, combinação farmacêutica